logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Cost effectiveness of Carvedilol for Heart Failure.

    Article - En anglais

    In this study, we examine the cost effectiveness of carvedilol for the treatment of chronic heart failure (CHF).

    We use a Markov model to project life expectancy and lifetime medical care costs for a hypothetical cohort of patients with CHF who were assumed alternatively to receive carvedilol plus conventional therapy (digoxin, diuretics, and angiotensin-converting enzyme inhibitors) or conventional therapy alone.

    Patients on carvedilol were assumed to experience a reduced risk of death and hospitalization for CHF, which is consistent with findings from the US Carvedilol Heart Failure Trials Program.

    The benefits of carvedilol were projected under 2 alternative scenarios.

    In the first ( « limited benefits »), benefits were conservatively assumed to persist for 6 months, the average duration of follow-up in these clinical trials, and then end abruptly.

    In the other ( « extended benefits »), they were arbitrarily assumed to persist for 6 months and then decline gradually over time, vanishing by the end of 3 years.

    We estimated our model using data from the US Carvedilol Heart Failure Trials Program and other i sources.

    For patients receiving conventional therapy alone, estimated life expectancy was 6.67 years ; corresponding figures for those also receiving carvedilol were 6.98 and 7.62 years under the limited and extended benefits scenarios, respectively. (...)

    Mots-clés Pascal : Insuffisance cardiaque, Carvédilol, Bloquant bêta-adrénergique, Analyse coût efficacité, Economie santé, Chimiothérapie, Traitement, Efficacité traitement, Homme, Vasodilatateur, Appareil circulatoire pathologie, Cardiopathie

    Mots-clés Pascal anglais : Heart failure, Carvedilol, Beta blocking agent, Cost efficiency analysis, Health economy, Chemotherapy, Treatment, Treatment efficiency, Human, Vasodilator agent, Cardiovascular disease, Heart disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0196469

    Code Inist : 002B02F04. Création : 16/11/1999.